Search Press releases Keywords From To 20 Nov 2024 UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa Read More 19 Nov 2024 Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity Read More 18 Nov 2024 Transparency notification BlackRock, Inc. Read More 18 Nov 2024 Transparency notification BlackRock, Inc. Read More 14 Nov 2024 New BIMZELX[®] (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis Read More 12 Nov 2024 Transparency notification BlackRock, Inc. Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 73 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
